Cerity Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $264M | Buy |
1,215,422
+15,739
| +1% | +$3.49M | 0.37% | 48 |
|
|
2025
Q4 | $274M | Buy |
1,199,683
+62,426
| +5% | +$14.2M | 0.4% | 43 |
|
|
2025
Q3 | $263M | Buy |
1,137,257
+5,121
| +0.5% | +$1.04M | 0.43% | 41 |
|
|
2025
Q2 | $210M | Buy |
1,132,136
+153,108
| +16% | +$28.5M | 0.37% | 48 |
|
|
2025
Q1 | $205M | Buy |
979,028
+105,110
| +12% | +$20.4M | 0.42% | 45 |
|
|
2024
Q4 | $158M | Buy |
873,918
+39,454
| +5% | +$7.25M | 0.34% | 57 |
|
|
2024
Q3 | $165M | Buy |
834,464
+154,337
| +23% | +$28.8M | 0.36% | 52 |
|
|
2024
Q2 | $117M | Sell |
680,127
-26,928
| -4% | -$4.46M | 0.31% | 64 |
|
|
2024
Q1 | $127M | Sell |
707,055
-260,835
| -27% | -$45M | 0.34% | 58 |
|
|
2023
Q4 | $90.4M | Buy |
967,890
+474,896
| +96% | +$69.2M | 0.3% | 77 |
|
|
2023
Q3 | $73.5M | Sell |
492,994
-156,373
| -24% | -$23M | 0.36% | 77 |
|
|
2023
Q2 | $87.5M | Buy |
649,367
+102,968
| +19% | +$15.1M | 0.34% | 65 |
|
|
2023
Q1 | $90.4M | Buy |
546,399
+108,335
| +25% | +$16.6M | 0.21% | 66 |
|
|
2022
Q4 | $72.3M | Buy |
438,064
+215,106
| +96% | +$33M | 0.46% | 52 |
|
|
2022
Q3 | $29.9M | Sell |
222,958
-14,149
| -6% | -$2.03M | 0.36% | 57 |
|
|
2022
Q2 | $36.3M | Sell |
237,107
-37,809
| -14% | -$5.78M | 0.4% | 52 |
|
|
2022
Q1 | $43.3M | Buy |
274,916
+17,862
| +7% | +$2.59M | 0.67% | 29 |
|
|
2021
Q4 | $33.9M | Buy |
257,054
+21,926
| +9% | +$2.59M | 0.52% | 40 |
|
|
2021
Q3 | $25.4M | Buy |
235,128
+6,377
| +3% | +$729K | 0.56% | 37 |
|
|
2021
Q2 | $25.8M | Buy |
228,751
+1,975
| +0.9% | +$222K | 0.56% | 36 |
|
|
2021
Q1 | $24.5M | Buy |
226,776
+107,276
| +90% | +$11.5M | 0.58% | 38 |
|
|
2020
Q4 | $12.8M | Buy |
119,500
+24,721
| +26% | +$2.38M | 0.41% | 50 |
|
|
2020
Q3 | $8.3M | Buy |
94,779
+16,636
| +21% | +$1.57M | 0.34% | 61 |
|
|
2020
Q2 | $7.67M | Buy |
78,143
+38,885
| +99% | +$3.42M | 0.42% | 48 |
|
|
2020
Q1 | $2.99M | Buy |
39,258
+6,827
| +21% | +$582K | 0.19% | 100 |
|
|
2019
Q4 | $2.87M | Sell |
32,431
-3,393
| -9% | -$282K | 0.15% | 120 |
|
|
2019
Q3 | $2.71M | Buy |
35,824
+1,110
| +3% | +$76.1K | 0.16% | 133 |
|
|
2019
Q2 | $2.52M | Buy |
34,714
+2,902
| +9% | +$228K | 0.16% | 132 |
|
|
2019
Q1 | $2.56M | Sell |
31,812
-10,894
| -26% | -$891K | 0.17% | 138 |
|
|
2018
Q4 | $3.94M | Buy |
42,706
+5,778
| +16% | +$508K | 0.26% | 91 |
|
|
2018
Q3 | $3.49M | Buy |
36,928
+968
| +3% | +$91.8K | 0.24% | 110 |
|
|
2018
Q2 | $3.33M | Buy |
35,960
+4,067
| +13% | +$397K | 0.25% | 108 |
|
|
2018
Q1 | $3.02M | Buy |
31,893
+585
| +2% | +$64.3K | 0.23% | 115 |
|
|
2017
Q4 | $3.03M | Sell |
31,308
-2,412
| -7% | -$227K | 0.2% | 116 |
|
|
2017
Q3 | $3M | Buy |
33,720
+8,581
| +34% | +$653K | 0.21% | 104 |
|
|
2017
Q2 | $1.82M | Buy |
25,139
+4,713
| +23% | +$317K | 0.15% | 123 |
|
|
2017
Q1 | $1.33M | Buy |
+20,426
| New | +$1.28M | 0.11% | 163 |
|
Other funds holding ABBV
VCM
VPM
Cerity Partners's ABBV Position: Q1 2026 in Review
Cerity Partners increased its AbbVie (ABBV) stake by 1.3% in Q1 2026, buying an estimated $3.49M and bringing the position to 1,215,422 shares worth $264M. The position accounts for 0.37% of the portfolio, ranked #48.
Cerity Partners first reported a position in ABBV in Q1 2017 and has held it in 37 quarters since. The position peaked at $274M in Q4 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Cerity Partners held 1,215,422 shares of AbbVie worth $264M as of Q1 2026.
- Cerity Partners bought 15,739 AbbVie shares in Q1 2026, an estimated $3.49M.
- AbbVie made up 0.37% of Cerity Partners's portfolio in Q1 2026, its #48 holding.
- Cerity Partners first reported a position in AbbVie in Q1 2017 and has held it in 37 quarters since.
- Cerity Partners's AbbVie position peaked at $274M in Q4 2025.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.